{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:49:14Z","timestamp":1771051754882,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006083","name":"Ministry of Defence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013428","name":"Stichting Spieren voor Spieren","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OR18-01"],"award-info":[{"award-number":["W.OR18-01"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.nmd.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T02:17:09Z","timestamp":1646619429000},"page":"419-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The therapeutic potential of soluble activin type IIB receptor treatment in a limb girdle muscular dystrophy type 2D mouse model"],"prefix":"10.1016","volume":"32","author":[{"given":"Ali","family":"Alqallaf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Engelbeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Palo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Cutrupi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa","family":"Tanganyika-de Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap","family":"Plomp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakthivel","family":"Vaiyapuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7131-749X","authenticated-orcid":false,"given":"Ketan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaike","family":"van Putten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2022.03.002_bib0001","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3233\/JND-150105","article-title":"The classification, natural history and treatment of the limb girdle muscular dystrophies","volume":"2","author":"Murphy","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2022.03.002_bib0002","first-page":"1","article-title":"Genetic basis of limb-girdle muscular dystrophies: the 2014 update","volume":"33","author":"Nigro","year":"2014","journal-title":"Acta Myol"},{"key":"10.1016\/j.nmd.2022.03.002_bib0003","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T","article-title":"Molecular basis of muscular dystrophies","volume":"23","author":"Cohn","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.03.002_bib0004","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s13311-018-0648-x","article-title":"The limb-girdle muscular dystrophies: is treatment on the horizon?","volume":"15","author":"Chu","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nmd.2022.03.002_bib0005","doi-asserted-by":"crossref","first-page":"18117","DOI":"10.1073\/pnas.0505996102","article-title":"Regulation of muscle growth by multiple ligands signaling through activin type II receptors","volume":"102","author":"Lee","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmd.2022.03.002_bib0006","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers","volume":"47","author":"Attie","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.03.002_bib0007","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1089\/hum.2012.056","article-title":"Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice","volume":"23","author":"Hoogaars","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nmd.2022.03.002_bib0008","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/rej.2009.0870","article-title":"Morphology and myofiber composition of skeletal musculature of the forelimb in young and aged wild type and myostatin null mice","volume":"12","author":"Elashry","year":"2009","journal-title":"Rejuvenation Res"},{"key":"10.1016\/j.nmd.2022.03.002_bib0009","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1073\/pnas.0604893104","article-title":"Lack of myostatin results in excessive muscle growth but impaired force generation","volume":"104","author":"Amthor","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmd.2022.03.002_bib0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/156652312800840577","article-title":"Interference with myostatin\/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy","volume":"12","author":"Amthor","year":"2012","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.nmd.2022.03.002_bib0011","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/mus.21944","article-title":"Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse","volume":"43","author":"Carlson","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.03.002_bib0012","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ajpath.2010.11.071","article-title":"Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy","volume":"178","author":"Pistilli","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2022.03.002_bib0013","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.03.002_bib0014","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/mt.2014.90","article-title":"Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy","volume":"22","author":"Relizani","year":"2014","journal-title":"Molecular Therapy: the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.nmd.2022.03.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182704","article-title":"Natural disease history of mouse models for limb girdle muscular dystrophy types 2D and 2F","volume":"12","author":"Pasteuning-Vuhman","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2022.03.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220665","article-title":"Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F","volume":"14","author":"Verhaart","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2022.03.002_bib0017","doi-asserted-by":"crossref","DOI":"10.3791\/51303-v","article-title":"Assessing functional performance in the mdx mouse model","author":"Aartsma-Rus","year":"2014","journal-title":"Journal of visualized experiments: JoVE"},{"key":"10.1016\/j.nmd.2022.03.002_bib0018","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1089\/hum.2019.006","article-title":"Gene delivery for limb-girdle muscular dystrophy type 2D by isolated limb infusion","volume":"30","author":"Mendell","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nmd.2022.03.002_bib0019","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.omtm.2019.10.002","article-title":"Plasmid-mediated gene therapy in mouse models of limb girdle muscular dystrophy","volume":"15","author":"Guha","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.nmd.2022.03.002_bib0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.gt.3302928","article-title":"AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency","volume":"14","author":"Bartoli","year":"2007","journal-title":"Gene Ther"},{"key":"10.1016\/j.nmd.2022.03.002_bib0021","first-page":"10","article-title":"Antimyostatin treatment in health and disease: the story of great expectations and limited success","author":"Nielsen","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.nmd.2022.03.002_bib0022","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1152\/physiolgenomics.00223.2010","article-title":"Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor","volume":"43","author":"Rahimov","year":"2011","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.nmd.2022.03.002_bib0023","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1152\/japplphysiol.00866.2009","article-title":"Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type","volume":"109","author":"Cadena","year":"2010","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.nmd.2022.03.002_bib0024","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/hum.2019.199","article-title":"Preclinical systemic delivery of adeno-associated \u03b1-sarcoglycan gene transfer for limb-girdle muscular dystrophy","volume":"32","author":"Griffin","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nmd.2022.03.002_bib0025","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16940","article-title":"Enhanced exercise and regenerative capacity in a mouse model that violates size constraints of oxidative muscle fibres","volume":"5","author":"Omairi","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.nmd.2022.03.002_bib0026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ydbio.2010.04.014","article-title":"A hypoplastic model of skeletal muscle development displaying reduced foetal myoblast cell numbers, increased oxidative myofibres and improved specific tension capacity","volume":"343","author":"Otto","year":"2010","journal-title":"Dev. Biol."},{"key":"10.1016\/j.nmd.2022.03.002_bib0027","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.semcdb.2017.11.005","article-title":"Nuclear positioning in skeletal muscle","volume":"82","author":"Roman","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.nmd.2022.03.002_bib0028","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00005072-199407000-00014","article-title":"Myofibers from Duchenne\/Becker muscular dystrophy and myositis express the intermediate filament nestin","volume":"53","author":"Sj\u00f6berg","year":"1994","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.nmd.2022.03.002_bib0029","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s40478-020-01048-8","article-title":"rAAV-related therapy fully rescues myonuclear and myofilament function in X-linked myotubular myopathy","volume":"8","author":"Ross","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.nmd.2022.03.002_bib0030","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/mt.2009.322","article-title":"Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice","volume":"18","author":"Dumonceaux","year":"2010","journal-title":"Molecular Therapy: the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.nmd.2022.03.002_bib0031","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2019.199","article-title":"Preclinical systemic delivery of adeno-associated alpha-sarcoglycan gene transfer for limb-girdle muscular dystrophy","author":"Griffin","year":"2021","journal-title":"Hum Gene Ther"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622000669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622000669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:12:35Z","timestamp":1760775155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896622000669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0960896622000669"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2022.03.002","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic potential of soluble activin type IIB receptor treatment in a limb girdle muscular dystrophy type 2D mouse model","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}